


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.


**Listing of Claims**

Claims 1 to 35. (Previously canceled).

Claim 36. (Previously presented) A compound having the formula



the (R) or (S) enantiomer thereof, or the cis or trans isomer thereof or a pharmaceutically acceptable salt thereof or solvate of the compound or salt thereof, wherein Z is



wherein Y is methylene; X is oxygen; n is 0; R<sup>1</sup> and R<sup>2</sup> are each hydrogen or halogen; and R<sup>3</sup> and R<sup>4</sup> together with the nitrogen atom to which they are attached form i) a saturated non-aromatic 3 to 7 membered monocyclic ring, said ring i) being unsubstituted or substituted with one or more (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy(C<sub>1</sub>-C<sub>4</sub>)alkyl, or hydroxy groups.

37. (Previously presented) The compound of Claim 36, wherein said compound is selected from the group consisting of:

(7R, 9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(6-piperidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-7-[6-(2,5-Dimethyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-7-(6-Azepan-1-ylmethyl-pyridin-2-yloxymethyl)-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-3-ylmethyl]-pyrrolidin-3-ol;

(7S, 9aS)-cis-7-(5-Azetidin-1-ylmethyl-pyridin-2-yloxymethyl)-2-benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methyl-aziridin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-7-(5-Azepan-1-ylmethyl-pyridin-2-yloxymethyl)-2-(benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methoxymethyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

(7S, 9aS)-cis-2-Benzo[d]isoxazol-3-yl-7-(5-piperidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7S, 9aS)-cis-7-(5-Azetidin-1-ylmethyl-pyridin-2-yloxymethyl)-2-benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazine;

(7S, 9aS)-cis-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methyl-aziridin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-2-ylmethyl]-pyrrolidin-3-ol;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-2-ylmethyl]-(R)-pyrrolidin-3-ol;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-2-ylmethyl]-(S)-pyrrolidin-3-ol;

(7S, 9aS)-cis-1-[6-(2-Benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy]-pyridin-3-ylmethyl]-pyrrolidin-(S)-3-ol;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy]-pyridin-3-ylmethyl]-piperidin-4-ol;

(7S, 9aS)-cis-1-[6-(2-Benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy]-pyridin-3-ylmethyl]-pyrrolidin-(R)-3-ol;

(7R, 9aS)-trans-7-(5-Azetidin-1-ylmethyl-pyridin-2-yloxymethyl)-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(6-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(5-piperidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;


(7S, 9aS)-cis-2-Benzo[d]isoxazol-3-yl-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7S, 9aS)-cis-2-Benzo[d]isoxazol-3-yl-7-(6-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine; and


(7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(6-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

or pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof.

38. (Previously presented) A pharmaceutical composition comprising a compound having the formula



the (R) or (S) enantiomer thereof, or the cis or trans isomer thereof or a pharmaceutically acceptable salt thereof or solvate of the compound or salt thereof, wherein Z is



wherein Y is methylene; X is oxygen; n is 0; R<sup>1</sup> and R<sup>2</sup> are each hydrogen or halogen; and R<sup>3</sup> and R<sup>4</sup> together with the nitrogen atom to which they are attached form i) a saturated non-aromatic 3 to 7 membered monocyclic ring, said ring i) being unsubstituted or substituted with one or more (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy(C<sub>1</sub>-C<sub>4</sub>)alkyl, or hydroxy groups, in combination with a pharmaceutically acceptable carrier.

39. (Previously presented) The composition of claim 38, wherein said compound is selected from the group consisting of

(7R, 9aS)-trans-7-[6-(2,6-Dimethyl-piperidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(6-piperidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-7-[6-(2,5-Dimethyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxymethyl]-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-7-(6-Azepan-1-ylmethyl-pyridin-2-yloxymethyl)-2-(5-fluorobenzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-3-ylmethyl]-pyrrolidin-3-ol;

(7S, 9aS)-cis-7-(5-Azetidin-1-ylmethyl-pyridin-2-yloxymethyl)-2-benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methyl-aziridin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-7-(5-Azepan-1-ylmethyl-pyridin-2-yloxymethyl)-2-(benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methoxymethyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

(7S, 9aS)-cis-2-Benzo[d]isoxazol-3-yl-7-(5-piperidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7S, 9aS)-cis-7-(5-Azetidin-1-ylmethyl-pyridin-2-yloxymethyl)-2-benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazine;

(7S, 9aS)-cis-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methyl-aziridin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-2-ylmethyl]-pyrrolidin-3-ol;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-2-ylmethyl]-(R)-pyrrolidin-3-ol;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-2-ylmethyl]-(S)-pyrrolidin-3-ol;

(7S, 9aS)-cis-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-3-ylmethyl]-pyrrolidin-(S)-3-ol;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-3-ylmethyl]-piperidin-4-ol;

(7S, 9aS)-cis-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-3-ylmethyl]-pyrrolidin-(R)-3-ol;

(7R, 9aS)-trans-7-(5-Azetidin-1-ylmethyl-pyridin-2-yloxymethyl)-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(6-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(5-piperidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7S, 9aS)-cis-2-Benzo[d]isoxazol-3-yl-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7S, 9aS)-cis-2-Benzo[d]isoxazol-3-yl-7-(6-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine; and

(7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(6-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

or pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof.

40. (Previously presented) A compound selected from

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-3-ylmethyl]-pyrrolidin-3-ol;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-3-ylmethyl]-piperidin-4-ol;

(7R, 9aS)-trans-7-(5-Azetidin-1-ylmethyl-pyridin-2-yloxymethyl)-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine; and

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(5-piperidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine, or pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof.

41. (Previously presented) The compound of claim 40 that is selected from

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-3-ylmethyl]-pyrrolidin-3-ol;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine; and

(7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine, or pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof.

42. (Previously presented) The compound of claim 40 that is selected from

(7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy)-pyridin-3-ylmethyl]-pyrrolidin-3-ol;

(7R, 9aS)-trans-2-Benzo[d]isoxazol-3-yl-7-[5-(2-methyl-pyrrolidin-1-ylmethyl)-pyridin-2-yloxymethyl]-octahydro-pyrido[1,2-a]pyrazine; and

(7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine, or pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof.

43. (Previously presented) The compound of claim 40 that is (7R, 9aS)-

trans-2-Benzo[d]isoxazol-3-yl-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-yloxymethyl)-octahydro-pyrido[1,2-a]pyrazine, or pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof.

44. (Previously presented) The compound of claim 40 that is selected from (7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy]-pyridin-3-ylmethyl]-pyrrolidin-3-ol; and (7R, 9aS)-trans-1-[6-(2-Benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazin-7-ylmethoxy]-pyridin-3-ylmethyl]-piperidin-4-ol, or pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof.
45. (Previously presented) The compound of claim 40 that is (7R, 9aS)-trans-7-(5-Azetidin-1-ylmethyl-pyridin-2-ylloxymethyl)-2-(5-fluoro-benzo[d]isoxazol-3-yl)-octahydro-pyrido[1,2-a]pyrazine, or pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof.
46. (Previously presented) The compound of claim 40 that is (7R, 9aS)-trans-2-(5-Fluoro-benzo[d]isoxazol-3-yl)-7-(5-pyrrolidin-1-ylmethyl-pyridin-2-ylloxymethyl)-octahydro-pyrido[1,2-a]pyrazine, or pharmaceutically acceptable salts thereof or solvate of the compound or salt thereof.
47. (Previously presented) A pharmaceutical composition comprising the compound of Claim 40, or the (*R*) or (*S*) enantiomer thereof, or the *cis* or *trans* isomer thereof, or a pharmaceutically acceptable salt thereof, or solvate of the compound or salt thereof; and a pharmaceutically acceptable carrier.
48. (Cancel)
49. (Currently amended) A method of treating a disorder selected from schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder; substance-induced psychotic disorder, ~~personality disorder of the paranoid type~~, personality disorder of the schizoid type, ~~panic disorder, phobias, obsessive compulsive disorder, stress disorders, generalized anxiety disorder, movement disorders involving Huntington's disease, dyskinesia associated with dopamine agonist therapy, Parkinson's disease, restless leg syndrome, disorders comprising as a symptom thereof a deficiency in cognition, dementias, mood disorders and episodes in a mammal; anxiety or psychotic disorders including schizophrenia, of the paranoid, disorganized, catatonic, undifferentiated, or residual type; schizophreniform~~



~~disorder; schizoaffective disorder of the delusional type or the depressive type; delusional disorder; psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type, agoraphobia; a specific phobia; social phobia; post-traumatic stress disorder; acute stress disorder; chemical dependencies: for alcohol, amphetamine, cocaine, heroin, phenobarbital, opiate, nicotine and benzodiazepines addiction; disorders comprising, as a symptom thereof, a deficiency in cognition, a subnormal functioning in one or more cognitive aspects; deficiency in memory, intellect, or learning and logic ability, in a particular individual relative to other individuals within the same general age population; reduction in any particular individual's functioning in one or more cognitive aspects, age-related cognitive decline; dementia, Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; Alzheimer's related dementia; delirium; amnesic disorder; post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit/hyperactivity disorder; mood disorders or mood episodes; major depressive episode of the mild, moderate or severe type, a manic or mixed mood episode, a hypomanic mood episode; a depressive episode with atypical features; a depressive episode with melancholic features; a depressive episode with catatonic features; a mood episode with postpartum onset; post-stroke depression; major depressive disorder; dysthymic disorder; minor depressive disorder; premenstrual dysphoric disorder; post-psychotic depressive disorder of schizophrenia; a major depressive disorder superimposed on a psychotic disorder; delusional disorder or schizophrenia; a bipolar disorder, bipolar I disorder, bipolar II disorder, and cyclothymic disorder, hypertension, depression; depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression, simple phobias, avoidant personality disorder, premature ejaculation, eating disorders; anorexia nervosa and bulimia nervosa, obesity, cluster headache, migraine, pain, memory disorders; neuroleptic-induced parkinsonism and tardive dyskinesias, endocrine~~

~~disorders; hyperprolactinaemia, vasospasm, vasospasm in the cerebral vasculature, cerebellar ataxia, gastrointestinal tract disorders involving changes in motility and secretion, negative symptoms of schizophrenia, mania, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, and Tourette's syndrome, trichotillomania, kleptomania, male impotence, cancer; small cell lung carcinoma, chronic paroxysmal hemicrania and headache associated with vascular disorders~~ in a mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of the compound of Claim 40, or the (*R*) or (*S*) enantiomer thereof, or the *cis* or *trans* isomer thereof, or a pharmaceutically acceptable salt thereof, or solvate of the compound or salt thereof.

50. (Cancel)

51. (Currently amended) A method of treating a disorder selected from schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder; substance-induced psychotic disorder, personality disorder of the paranoid type, personality disorder of the schizoid type, ~~panic disorder, phobias, obsessive compulsive disorder, stress disorders, generalized anxiety disorder, movement disorders involving Huntington's disease, dyskinesia associated with dopamine agonist therapy, Parkinson's disease, restless leg syndrome, disorders comprising as a symptom thereof a deficiency in cognition, dementias, mood disorders and episodes in a mammal; anxiety or psychotic disorders including schizophrenia, of the paranoid, disorganized, catatonic, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder of the delusional type or the depressive type; delusional disorder; psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type, agoraphobia; a specific phobia; social phobia; post-traumatic stress disorder; acute stress disorder; chemical dependencies: for alcohol, amphetamine, cocaine, heroin, phenobarbital, opiate, nicotine and benzodiazepines addiction; disorders comprising, as a symptom thereof, a deficiency in cognition, a subnormal functioning in one or more cognitive aspects; deficiency in memory, intellect, or learning and logic ability, in a particular individual relative to other individuals within the same general age population; reduction in any particular individual's functioning in one or more cognitive aspects, age-related cognitive decline; dementia, Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial~~

tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; Alzheimer's related dementia; delirium; amnesic disorder; ~~post-traumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention-deficit/hyperactivity disorder; mood disorders or mood episodes; major depressive episode of the mild, moderate or severe type, a manic or mixed mood episode, a hypomanic mood episode; a depressive episode with atypical features; a depressive episode with melancholic features; a depressive episode with catatonic features; a mood episode with postpartum-onset; post-stroke depression; major depressive disorder; dysthymic disorder; minor depressive disorder; premenstrual dysphoric disorder; post-psychotic depressive disorder of schizophrenia; a major depressive disorder superimposed on a psychotic disorder; delusional disorder or schizophrenia; a bipolar disorder, bipolar I disorder, bipolar II disorder, and cyclothymic disorder, hypertension, depression; depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression, simple phobias, avoidant personality disorder, premature ejaculation, eating disorders; anorexia nervosa and bulimia nervosa, obesity, cluster headache, migraine, pain, memory disorders; neuroleptic-induced parkinsonism and tardive dyskinesias, endocrine disorders; hyperprolactinaemia, vasospasm, vasospasm in the cerebral vasculature, cerebellar ataxia, gastrointestinal tract disorders involving changes in motility and secretion, negative symptoms of schizophrenia, mania, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, and Tourette's syndrome, trichotillomania, kleptomania, male impotence, cancer; small cell lung carcinoma, chronic paroxysmal hemicrania and headache associated with vascular disorders~~ in a mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of the compound of Claim 36, or the (*R*) or (*S*) enantiomer thereof, or the *cis* or *trans* isomer thereof, or a pharmaceutically acceptable salt thereof, or solvate of the compound or salt thereof.